{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:57:00Z","timestamp":1788483420403,"version":"build-2803163510"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Singapore","award":["DR1823003983"],"award-info":[{"award-number":["DR1823003983"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,6,25]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>To describe the functional outcomes of patients with diabetic macular oedema (DME) non-responsive to bevacizumab switched to ranibizumab or aflibercept over 1 year and the demographic and anatomic predictors of these functional outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a retrospective real-world cohort study, 76 consecutive patients with DME non-responsive to bevacizumab were reviewed at baseline and 12 months after switch to ranibizumab or aflibercept. Visual acuity (VA) and optical coherence tomography features such as central retinal thickness were assessed. Multiple logistic regression was performed to determine predictors for outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From baseline to 1 year, the overall best-corrected VA improved by LogMAR 0.015\u00b10.19 with no difference between patients who switched to ranibizumab or aflibercept (LogMAR 0.017\u00b10.21\u2009vs LogMAR 0.013\u00b10.17, p=0.92). Ranibizumab patients had more reduction in central subfield thickness (CST) (390.13\u2009\u00b5m vs 334.20\u2009\u00b5m, p=0.033) than aflibercept patients. Baseline HbA1c (p=0.012) and number of bevacizumab injections (p=0.040) were significantly associated with gain in VA, while change in CST was a strong predictor of VA change (p&lt;0.01). Aflibercept patients were more likely to gain vision after 6 months but not at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world study, improvements in functional outcomes can still be gained after switching anti-vascular endothelial growth factor in bevacizumab non-responders. Both ranibizumab and aflibercept were comparable and effective treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002178","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:45:17Z","timestamp":1754037917000},"page":"e002178","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study)"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2119-787X","authenticated-orcid":false,"given":"Louis W","family":"Lim","sequence":"first","affiliation":[{"name":"Ophthalmology, Woodlands Health, Singapore"},{"name":"National Healthcare Group Eye Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Choy","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Jun","family":"Song","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Kiong","family":"Ngo","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"},{"name":"Hebei Provincial Eye Hospital, Hebei, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-7537","authenticated-orcid":false,"given":"Zheng Xian","family":"Thng","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Fang","family":"Mi","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Qiang","family":"Soh","sequence":"additional","affiliation":[{"name":"Ophthalmology, Woodlands Health, Singapore"},{"name":"National Healthcare Group Eye Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Lilian","sequence":"additional","affiliation":[{"name":"Ophthalmology, Woodlands Health, Singapore"},{"name":"National Healthcare Group Eye Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Yu Hang","family":"Chin","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Jhi Wen","family":"Chia","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustinus","family":"Laude","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S","family":"Tan","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tock Han","family":"Lim","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issac","family":"Too","sequence":"additional","affiliation":[{"name":"Novartis AG, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Y","family":"Gan","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Singapore"},{"name":"Ophthalmology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2026010721203400000_10.1.e002178.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.08.022"},{"key":"2026010721203400000_10.1.e002178.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"2026010721203400000_10.1.e002178.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"2026010721203400000_10.1.e002178.4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00592-019-01310-z","article-title":"Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study","volume":"56","author":"Busch","year":"2019","journal-title":"Acta Diabetol"},{"key":"2026010721203400000_10.1.e002178.5","doi-asserted-by":"publisher","DOI":"10.1159\/000495623"},{"key":"2026010721203400000_10.1.e002178.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"2026010721203400000_10.1.e002178.7","doi-asserted-by":"publisher","DOI":"10.1159\/000458539"},{"key":"2026010721203400000_10.1.e002178.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.007"},{"key":"2026010721203400000_10.1.e002178.9","first-page":"346","article-title":"Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularization","volume":"49","author":"Gasperini","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721203400000_10.1.e002178.10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jcjo.2012.01.003","article-title":"Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration","volume":"47","author":"Kent","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"2026010721203400000_10.1.e002178.11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/OPTH.S280644","article-title":"Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis","volume":"15","author":"Pessoa","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"2026010721203400000_10.1.e002178.12","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2147\/OPTH.S316271","article-title":"Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema","volume":"15","author":"Alsaedi","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"2026010721203400000_10.1.e002178.13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3928\/23258160-20170829-10","article-title":"Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema","volume":"48","author":"Banaee","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2026010721203400000_10.1.e002178.14","doi-asserted-by":"crossref","first-page":"OCT224","DOI":"10.1167\/iovs.15-18869","article-title":"Optical Coherence Tomography Angiography Evaluation of the Parafoveal Vasculature and Its Relationship With Ocular Factors","volume":"57","author":"Tan","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721203400000_10.1.e002178.15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000770"},{"key":"2026010721203400000_10.1.e002178.16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1167\/iovs.16-20855","article-title":"Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab","volume":"58","author":"Giocanti-Aur\u00e9gan","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721203400000_10.1.e002178.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.02.036"},{"key":"2026010721203400000_10.1.e002178.18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/IAE.0000000000001626","article-title":"PREDICTIVE VALUE OF OPTICAL COHERENCE TOMOGRAPHIC FEATURES IN THE BEVACIZUMAB AND RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (BRDME) STUDY","volume":"38","author":"Fickweiler","year":"2018","journal-title":"Retina"},{"key":"2026010721203400000_10.1.e002178.19","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307249"},{"key":"2026010721203400000_10.1.e002178.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-020-01582-y","article-title":"Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study","volume":"20","author":"Tan","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"2026010721203400000_10.1.e002178.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.021"},{"key":"2026010721203400000_10.1.e002178.22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40123-024-01067-x","article-title":"One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study","volume":"14","author":"Yozgat","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"2026010721203400000_10.1.e002178.23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/IAE.0000000000004096","article-title":"Anti-vascular endothelial growth factor treatment in diabetic macular edema: Results from a large single-center cohort with bevacizumab as first-line therapy: Results from a large single-center cohort with bevacizumab as first-line therapy","volume":"44","author":"Zur","year":"2024","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2026010721203400000_10.1.e002178.24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005441","article-title":"Effect of age and sex on retinal layer thickness and volume in normal eyes","volume":"95","author":"Won","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026010721203400000_10.1.e002178.25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.eye.6702789","article-title":"Assessment of macular retinal thickness and volume in normal eyes and highly myopic eyes with third-generation optical coherence tomography","volume":"22","author":"Wu","year":"2008","journal-title":"Eye (Lond)"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:21:11Z","timestamp":1767849671000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjophth-2025-002178"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002178","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}